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Abstract
Pain in chronic pancreatitis (CP) shows similarities 
with other visceral pain syndromes (i.e. , inflammatory 
bowel disease and esophagitis), which should thus 
be managed in a similar fashion. Typical causes of 
CP pain include increased intrapancreatic pressure, 
pancreatic inflammation and pancreatic/extrapancreatic 
complications. Unfortunately, CP pain continues to be 
a major clinical challenge. It is recognized that ongoing 
pain may induce altered central pain processing, 
e.g. , central sensitization or pro-nociceptive pain 
modulation. When this is present conventional pain 
treatment targeting the nociceptive focus, e.g. , opioid 
analgesia or surgical/endoscopic intervention, often 
fails even if technically successful. If central nervous 
system pain processing is altered, specific treatment 
targeting these changes should be instituted (e.g. , 
gabapentinoids, ketamine or tricyclic antidepressants). 
Suitable tools are now available to make altered central 
processing visible, including quantitative sensory testing, 
electroencephalograpy and (functional) magnetic 
resonance imaging. These techniques are potentially 
clinically useful diagnostic tools to analyze central pain 
processing and thus define optimum management 
approaches for pain in CP and other visceral pain 
syndromes. The present review proposes a systematic 
mechanism-orientated approach to pain management in 
CP based on a holistic view of the mechanisms involved. 
Future research should address the circumstances under 
which central nervous system pain processing changes 
in CP, and how this is influenced by ongoing nociceptive 
input and therapies. Thus we hope to predict which 
patients are at risk for developing chronic pain or not 
responding to therapy, leading to improved treatment of 
chronic pain in CP and other visceral pain disorders.
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Core tip: Pain in chronic pancreatitis (CP) shows 
many similarities with other visceral pain syndromes. 
CP pain frequently leads to peripheral and central 
sensitization. When the latter is present, treating the 
nociceptive focus, with i.e. , analgesic therapy, surgical 
or endoscopic procedures for local complications may 
fail even after technically successful procedures. In 
this case, treatment must be aimed at the central 
nervous system (CNS). Suitable tools to visualize altered 
central processing include quantitative sensory testing, 
electroencephalograpy and magnetic resonance imaging. 
Future research should be aimed at the circumstances 
under which CNS processing changes and how this is 
influenced by pain and therapies. 
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INTRODUCTION
Chronic pancreatitis (CP) involves progressive inflammatory 
changes of  the pancreas resulting in morphological 
alterations and loss of  pancreatic endocrine and exocrine 
function[1]. Quality of  life is impaired and life expectancy 
is reduced[2,3]. The two main clinical manifestations of  
CP are pancreatic insufficiency and (chronic) abdominal 
pain. Pancreatic insufficiency is marked by exocrine 
dysfunction resulting in impaired food digestion and 
absorption, and endocrine dysfunction which results 
in diabetes mellitus[1]. Pain in CP is considered to be 
of  visceral origin. When compared to other (chronic) 
visceral pain syndromes there are many similarities with 
the pain presentation of  CP patients. The pain of  CP is 
typically present as chronic epigastric pain, often radiating 
to the back, severe, dull, worse after eating and exhibiting 
episodic flares. This conforms to typical clinical 
characteristics of  visceral pain which are: (1) the pain 
is not always simply or directly linked to morphological 
changes of  the diseased organ; (2) pain is diffuse and 
poorly localized; (3) the pain may be referred to other 
locations; and (4) the pain is accompanied by motor 
and autonomic reflexes (vomiting, nausea and muscle 
tension)[4]. These parallels suggest that CP pain provides 
a useful model for the diagnosis and treatment of  visceral 
pain syndromes with an identifiable nociceptive source in 
general.
Pain management in CP is at present mostly aimed 
at the nociceptive source, the pancreas. General recom­
mendations include correction of  pancreatic insufficiency 
and management of  local complications, flanked by 
dietary modifications and cessation of  alcohol use and 
smoking[1]. Currently a conservative step­up approach 
is advocated for pain treatment in CP, consisting of  
symptomatic pain relief  and dealing with the pancreas as 
nociceptive source. For symptomatic pain relief, patients 
are treated with analgesics based on the “pain relief  
ladder” provided by the World Health Organization[5]. 
When such analgesic therapy is not successful, patients 
usually are referred for endoscopic interventions to 
attempt to reduce nociceptive input from the diseased 
pancreas. Eventually, patients may be referred for 
invasive surgical intervention if  pain still persists despite 
prolonged analgesic (usually opioid) use and multiple 
endoscopic interventions (up to 75% of  all patients).
Usually endoscopic interventions are performed 
for pancreatic duct strictures (stenting) and pancreatic 
duct stones (extracorporal shockwave therapy). Multiple 
surgical procedures have been described in the literature, 
all with different indications and success rates[6]. Drainage 
procedures like the pancreaticojejunostomy are performed 
for an enlarged pancreatic duct. When an enlarged 
pancreatic duct with an inflammatory mass in the pancreatic 
head is present, usually a Frey or Beger procedure is 
performed. Indications for (partial) pancreatic resections, 
i.e., pancreaticoduodenectomy, distal pancreatectomy and 
total pancreatectomy, are inflammatory masses in the 
head or tail of  the pancreas, or failure of  other therapies. 
Alternative approaches for dealing with the pancreas as a 
nociceptive source include deafferentation techniques such 
as nerve blocks and denervation procedures like bilateral 
thoracoscopic sphlanchnicectomy, which have shown to be 
beneficial for pain reduction in CP patients[7]. The success 
rate in terms of  pain reduction after endoscopy or surgery 
is highly variable[6]. The optimal timing of  interventions 
and which patients should be treated endoscopically or 
surgically continues to be intensively debated[6]. Despite 
these many management options, a significant number of  
chronic pancreatitis patients continue to experience pain 
even after conventional successful treatments, resulting in 
recurrent hospitalization, opioid dependence and severely 
impaired quality of  life[8,9]. 
It is increasingly accepted that in many patients with 
refractory chronic pain, the pain may be the result of  
abnormal central pain processing which should be taken 
into account and targeted when pain management is 
planned[10]. This is in line with the key new insight of  the 
last two to three decades of  pain research, demonstrating 
that the central nervous system is not hard­wired, but 
rather highly plastic in the face of  ongoing nociceptive 
input, exhibited as extensive alterations in central pain 
processing[10]. These changes typically involve increased 
pain sensitivity and facilitatory changes in modulation of  
painful inputs[11­13]. Further support for this view comes 
from recent successful studies with non­classical analgesic 
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medication, i.e., S­ketamine and pregabalin, which targets 
mainly the central nervous system, and which has been 
shown to be effective in both visceral and somatic 
chronic pain syndromes[11,14,15]. 
To optimize (pain) treatment in CP, it is thus evident 
that we need to move away from approaches exclusively 
based on dealing with peripheral nociceptive input from 
the pancreas towards more holistic strategies taking 
into account alterations in central pain processing due 
to ongoing nociceptive inputs. The aim of  this review 
is to highlight the recent progress in understanding 
the central mechanisms underlying chronic pain in CP 
and its impact on pain management. We present the 
evidence presently available that such central changes 
take place and operate in the human clinical context. 
Next, we focus on the diagnostics that are currently 
available to measure/visualize changes in central pain 
processing and how these are related to chronic pain in 
CP and other chronic abdominal visceral pain syndromes. 
Finally, based on these diagnostics we propose a new 
systematic mechanism­orientated approach to diagnosing 
and treating pain in CP as an example of  an abdominal 
visceral pain syndrome.
A SYSTEMATIC MECHANISM-
ORIENTATED APPROACH TO CHRONIC 
PAIN
Even after tissue healing, pain may persist as chronic 
pain with a major impact on quality of  life. To date, 
the majority of  publications on chronic pain adopt 
an empirical approach to the treatment of  such pain, 
primarily based on dealing with the putative peripheral 
nociceptive source of  the pain. At present, a holistic 
systematic mechanism­orientated approach to the 
prevention and treatment of  chronic pain is lacking.
Key: Altered pain processing
A key insight has been that nervous system processing 
of  pain is not hard­wired: sensory processing in the 
central nervous system typically changes as a result of  
noxious sensory inputs[16]. Acute nociception initially 
results in increased pain sensitivity (hyperalgesia) 
affecting the peripheral and central nervous system. 
When ongoing nociception (due to ongoing damage to 
tissues and nerves) is present, it initially sensitizes the 
peripheral nervous system. Subsequently, such ongoing 
nociceptive barrage will excite the spinal cord, brainstem 
and brain leading to central sensitization. In the end the 
whole nervous system may become sensitized, leading 
to exaggerated pain with minor stimuli (hyperalgesia) 
or even pain without nociceptive input (allodynia)[16­18]. 
Counteracting modulatory responses to nociceptive 
input like descending inhibition may fail as well, or even 
become facilitatory, resulting in more pain[9]. 
Four key questions
To achieve a holistic and systematic mechanism­
orientated approach to chronic pain four key questions 
need to be answered[18]. 
What is the source of  nociception? The majority of  
chronic pain disorders start off  with a nociceptive source. 
Knowledge of  the source enables us to aim our therapy 
at it and provides us with information regarding the 
type and intensity of  nociception (e.g., visceral vs somatic 
pain).
Is nociceptive transmission altered? A common 
reason for altered nociceptive transmission by peripheral 
nerves to the central nervous system is peripheral nerve 
sensitization and damage. Nerve damage is a strong 
predictor for pain that is difficult to control or treat 
and can become a source of  nociceptive input in itself. 
Nerve damage is associated with extensive and aggressive 
alteration in central nervous system function[19]. In 
addition, cytokines, hormones and other acute phase 
proteins may be released due to pathological processes 
and may facilitate sensitization of  the central nervous 
system, e.g., via humoral pathways[9,20]. 
Is central pain processing altered? The first alteration 
in central nervous system processing to be taken into 
account is central sensitization, defined as an increased 
responsiveness of  central pain transmitting neurons[9]. 
The presence and persistence of  central sensitization 
affects both disease prognosis and effectiveness of  
therapy in chronic pain conditions. More extensive spread 
of  central sensitization (generalized hyperalgesia) is 
associated with more pain. When central sensitization is 
present, therapy targeting only the source of  nociception 
(the disease site) will be relatively ineffective. Thus drug 
treatment modulating the sensitization of  the central 
nervous system need to be instituted. Examples of  agents 
achieving this are gabapentinoids and antidepressants. 
Secondly, the state of  descending central pain modulation 
must also be taken into account. If  there is a pro­
nociceptive (facilitatory) shift in central pain modulation, 
this has a negative effect on prognosis and requires 
specific treatment strategies[21]. 
Is altered central processing (still) dependent on 
peripheral nociceptive drive? If  altered central processing 
becomes independent of  peripheral nociceptive drive this 
further worsens the prognosis for controlling pain, and 
therapies aimed at controlling the nociceptive input from 
the source of  disease are highly prone to failure. In this 
context, specific treatment dealing with altered central 
pain processing is mandatory e.g., gabapentinoids and 
antidepressants[18]. 
Implications
In summary, increasing evidence shows that (ongoing) 
nociceptive input results in altered central pain processing 
and should be taken into account in the management 
of  chronic pain. However knowledge is lacking on 
how chronic painful inputs leads to altered central 
49 January 7, 2015|Volume 21|Issue 1|WJG|www.wjgnet.com
Bouwense SAW et al . Chronic pancreatitis pain
50 January 7, 2015|Volume 21|Issue 1|WJG|www.wjgnet.com
noxious inhibitory controls or DNIC). In the case of  
CPM a test stimulation is applied (e.g., pain threshold, 
pain score), afterwards a conditioning stimulus is applied 
(e.g., cold pressor task via ice water bucket immersion) 
and then again the test stimulation is applied. The 
difference between the two test stimuli signals the size of  
inhibitory or facilitatory descending modulation. When 
central sensitization is present descending modulatory 
mechanisms often fail, due to a decreased activity in the 
inhibitory pathway of  the spinal cord and an increase 
in facilitatory pathway activity, resulting in a further 
increase in pain (Figure 1)[27,28]. QST is increasingly used 
to compare pain sensitivity before and after interventions 
for patients and healthy controls in acute and chronic 
pain disorders.
EEG 
EEG is the recording of  electrical brain activity, 
generated by synchronous activity of  thousands of  
millions of  neurons in the cortex. Neural networks are 
usually randomly active at any given time in a resting 
state, and can be synchronized in response to an external 
stimulus. Therefore, EEG can be used in chronic pain 
conditions to study the brains’ default state reflected by 
the resting state EEG (static element) and brain activity 
due to external stimuli reflected by event related or 
evoked brain potentials (dynamic element). As early as 
1953, the EEG was already being studied in patients with 
pain due to peptic ulcers and functional gastric disorders 
by Kirschbaum et al[29]. Their study is an early example 
of  the recognition of  the brain­gut axis as a possible 
substrate for visceral pain syndromes. Although the use 
of  EEG can be demanding and complex, this technique 
is a potentially useful non­invasive method for clinical 
practice. EEG has a poor spatial resolution, but superior 
millisecond­range temporal resolution compared to other 
neurodiagnostic instruments such as positron emission 
tomography or fMRI, enabling direct measurements of  
neuronal processing[30]. 
Resting state EEG: The resting state EEG is commonly 
analyzed by transforming data from the time domain 
into the frequency domain. Spontaneous brain activity in 
the frequency domain is divided into different frequency 
bands (delta = 1­3.5 Hz, theta = 3.5­7.5 Hz, alpha = 
7.5­13 Hz, and beta = 13­32 Hz). The awake human 
brain activity recorded during rest is typically dominated 
by oscillations in the alpha frequency band. This 
dominant alpha activity is most prominent over parietal 
and occipital cortices, and is largest when the eyes are 
closed[31]. Recent developments in cognitive neuroscience 
suggests that alpha activity reflects selective cortical 
inhibition, rather than neural idling[32]. 
Alterations in the brains’ default state as reflected by 
resting state EEG, particularly in the alpha band, have 
been observed in multiple studies in various chronic pain 
conditions. Typically these changes consist of  a shift 
of  peak alpha or theta frequency to lower frequencies 
and/or a reduction in alpha or theta power[33­35]. It seems 
pain processing, and how this is influenced by disease 
progression and therapeutic interventions. Hence, the 
key to better treatment of  chronic pain is measuring or 
visualizing the changes in the central nervous system ­ 
or neuroplasticity ­ that accompany the development 
and existence of  chronic pain conditions. Together 
with measurements before and after treatment, the 
introduction of  such systematic mechanism­orientated 
diagnostics will provide the basis for optimization of  
treatment indications and schedules.
A SYSTEMATIC MECHANISM-
ORIENTATED APPROACH TO 
DIAGNOSING ALTERED PAIN 
PROCESSING IN CHRONIC PAIN
Quantitative sensory testing (QST), electroencephalograpy 
(EEG) and (functional) magnetic resonance imaging 
[(f)MRI] have increasingly been used in chronic pain 
disorders to describe changes in structure and function 
of  the central nervous system. In the next paragraphs we 
will give a short introduction to QST, EEG and (f)MRI 
and their use in chronic pain conditions.
QST 
The basis for QST was laid by Ulf  Lindblom in the 
1950s[22]. He was one of  the first to describe the use of  
physiologic stimulation of  the peripheral afferent unit in 
animals to test sensory processing. Later on he applied 
his experience in patients with sensory abnormalities i.e., 
chronic pain, which was the start of  the use of  QST in 
humans[23]. 
QST gives clinicians and researchers the opportunity 
to study abnormalities in the sensory system and 
characterize mechanisms underlying pathologic pain 
disorders. Compared to bedside clinical tests, QST is 
reliable and quantifies both the test stimulus (i.e., heat 
or pressure) and the patient’s response (i.e., pain)[24,25]. 
Somatosensory evoked responses to electrical, mechanical, 
thermal or chemical test modalities are involved in 
QST[26]. The stimulus is applied in a systematic fashion 
to an anatomical site (skin, muscle, joint or viscera like 
the esophagus or sigmoid). Stimulus intensity is gradually 
increased until the subject reaches a predefined sensory 
threshold (e.g., sensation or pain). By using multiple 
stimuli with differing intensities it is possible to construct 
a stimulus­response relationship (or curve) characterizing 
the subjects’ state of  pain processing. This stimulus­
response relationship is particularly useful as it also 
involves suprathreshold stimulation, particularly relevant 
to clinical pain. Measurements at the affected site or sites 
more distant are used to differentiate between signs of  
peripheral and (spinal or supraspinal) central sensitization.
Descending pain modulation (“pain inhibits pain”, 
a response to a noxious stimulus is inhibited by another 
noxious stimulus) is measured using the conditioned pain 
modulation paradigm (CPM, formerly known as diffuse 
Bouwense SAW et al . Chronic pancreatitis pain
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unlikely that alpha activity is directly related to the pain 
experience, as a correlation between pain intensity and 
alpha power is absent[35]. 
Evoked brain potentials: Event­related potentials or 
evoked potentials (EPs) are voltage polarity changes 
in the EEG time­locked to the onset of  an external 
stimulus. They reflect the summed activity of  postsynaptic 
potentials produced when a large number of  similarly 
oriented neurons fire in synchrony while processing 
information[36]. EPs are traditionally extracted from the 
EEG by averaging similar repetitive stimuli within a 
stimulus block. Human EPs can be divided into two parts. 
The early components peaking roughly within the first 
100 milliseconds after stimulus presentation are termed 
“sensory” or “exogenous” as they depend largely on the 
physical parameters of  the stimulus. In contrast, later 
components of  EPs reflect the manner in which the 
subject evaluates the stimulus and are termed “cognitive” 
or “endogenous” EPs as they examine information 
processing[37]. Alterations in evoked potentials are 
traditionally studied in the amplitudes and latencies of  the 
(positive and negative) potential peaks, and can also be 
studied in the time frequency domain[38]. 
In order to obtain evoked potentials that are specific 
to nociceptive input, such input should be the result 
of  physiological processing of  nociceptive stimuli, i.e., 
involving selective activation of  nociceptive Aδ/C­fibers 
in the periphery and recording resultant EPs generated 
in the cortex[39]. Brain mapping studies have established 
a positive relationship between the intensity of  pain 
reported to nociceptive selective laser stimuli and EP 
amplitude[40]. In the context of  evoked EEG studies, it 
must be noted that the experimental visceral electrical 
stimulation of  large and small peripheral afferents that 
is generally applied to different gut segments is painful 
but not nociception specific[41]. Whether EPs resulting 
from stimuli entirely selective for nociceptive peripheral 
afferents represent the experience of  pain or a more 
generalized response of  heightened attention or arousal 
to afferent stimuli is current topic of  debate[40,42,43]. 
Mouraux and Iannetti demonstrated that laser­evoked 
EEG responses reflect neural activities equally involved 
in processing nociceptive and non­nociceptive sensory 
inputs[43]. Thus, a stimulus entirely selective for nociceptive 
peripheral afferents does not imply that the elicited 
brain activity is nociception specific. However, even if  
EPs reflect neuronal activities that are unspecific for the 
(4) Cortical reorganisation,
loss of inhibition
Figure 1  Summarizes the views presented above regarding the mechanisms underlying pain. This figure illustrates the concept of spread of altered central 
pain processing (progression marked via letters) following ongoing nociceptive input due to tissue and nerve damage (progression marked by numbers). This figure is 
based on the original figure of ref[18]. CPM: Conditioned pain modulation.
Brain
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affective and cognitive
processing
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nociceptive system, their generation still relies on the 
consequences of  nociceptive activation and resultant 
changes in CNS state at both peripheral and central 
levels[43].
(f)MRI: (f)MRI has been increasingly used to describe 
brain activity and structural changes in chronic pain 
disorders. (f)MRI uses different techniques to measure 
functional brain activity. Changes in oxygenated and 
deoxygenated hemoglobin can be measured by the 
blood oxygenation level dependent technique[44]. By this 
technique the change in oxygenation (reflecting neuronal 
activity) in different areas of  the brain can be estimated. 
Recently diffusion tensor imaging (DTI) has been used to 
measure changes in gray and white matter microstructure, 
and connectivity between brain areas[45]. Other functional 
techniques are signal enhancement by extravascular 
water protons and arterial spin labeling which allows the 
measurement of  whole brain cerebral blood flow[46,47]. 
Taken together, the (f)MRI techniques allow assess­
ment of  the neural activation induced by stimuli like 
pain, and the structural neuroplastic changes induced by 
a long­lasting pain input. Compared to QST and EEG 
the advantage of  (f)MRI is that it can take into account 
anatomy and can quantify the area of  neuronal activity. 
The downside of  the technique is that it is difficult 
to assess whether neural activity has a facilitatory or 
inhibitory effect on the pain processing. The main use 
for fMRI lies in anatomical resting state and activation 
studies[48]. Increasing evidence from studies using these 
tools has provided us with more information on central 
pain processing and how it can be influenced by disease 
progression and treatments.
Clinical diagnostics of pain processing
For implementation in the clinical context, a suitable 
tool to diagnose altered pain processing in chronic pain 
should fulfill the following criteria[18]. 
The tool should be validated and suitable for a 
clinical setting with a minimal burden for the patient. 
Measurements should be easy to reproduce and stimuli 
should be standardized so data can be compared between 
patients and populations. A tool that is easy to use can 
be used in an outpatient setting and has a low burden, 
increases patient compliance and makes the method more 
practical for clinical use.
The tool should reveal altered pain processing for 
both superficial and deep tissue stimulation. Differences 
in deep and superficial tissue stimulation may help 
discriminate between somatic and visceral origin of  
pain and the extent of  central sensitization (e.g., somato­
somatic, viscero­visceral and viscera­somatic spread of  
hyperalgesia).
The tool should contain static (pain sensitivity) and 
dynamic (pain modulation) elements. Static measurements 
provide insights into basal pain sensitivity (e.g., central 
sensitization) and dynamic measurements test how the 
body actively modulates nociceptive input.
The tool should sensitively assess changes in sensitization 
of  pain processing as well as alterations in state of  cortical/
descending modulation. In the context of  sensitized signal 
processing by the central nervous system, this will help 
differentiate e.g., between a situation of  ongoing nociceptive 
input directly sensitizing central processing and pro­
nociceptive alterations of  descending nociceptive control by 
brainstem and brain (Figure 1). 
Application of  such a holistic approach to chronic 
pain is the basis for systematic mechanism­orientated 
pain management enabling: (1) diagnosis and prognosis 
of  chronic pain; (2) rationale for treatment choice and 
responder identification; and (3) monitoring of  chronic 
pain and its treatment[18]. 
EVIDENCE FOR A SYSTEMATIC 
MECHANISM-ORIENTATED APPROACH 
TO CHRONIC PAIN
In the next paragraphs we will focus on QST, EEG and 
(f)MRI research documenting the reality of  altered pain 
processing in chronic visceral pain disorders such as 
chronic pancreatitis and thus providing further evidence 
for the feasibility of  achieving a systematic mechanism­
orientated approach in clinical practice.
What is the source of nociception?
In the literature the following pathophysiological 
mechanisms have most commonly been suggested 
as causes of  pain in CP: (1) increased intrapancreatic 
pressure within the parenchyma and/or pancreatic duct 
causing tissue ischemia (due to pancreatic duct strictures 
and stones); (2) inflammation of  the pancreas; and 
(3) pancreatic and extrapancreatic complications (i.e., 
pseudocysts, bile duct/duodenal strictures and peptic 
ulcers)[49­53]. The exact pathophysiology of  chronic 
pancreatitis is still unknown and which mechanisms 
starts first are still subject to debate i.e., are duct strictures 
caused by tissue ischemia or inflammation or both?
Is nociceptive transmission altered?
In the past years, increasing evidence has been published 
regarding altered nociception transmission (e.g., nerve 
damage, peripheral sensitization) in chronic pain patients 
like CP[12,16,27,54]. In CP transmission of  nociceptive input 
from the pancreas to the spinal cord can be altered and 
influenced by lesions in intrapancreatic and peripheral 
nerves, as described in histological studies[55,56]. These 
changes are comparable with other neuropathic pain 
disorders[9,57]. Not only an increase of  excitability of  
nerves innervating the pancreas, but also structural 
changes of  nerves in the pancreas may be a part of  
the problem. Hence, hypertrophy, increased neural 
density and neuritis of  intrapancreatic nerves have been 
reported to be associated with pain in CP patients[58,59]. 
Ongoing nociceptive input due to the inflammation 
of  the pancreas and its local complications may lead 
Bouwense SAW et al . Chronic pancreatitis pain
53 January 7, 2015|Volume 21|Issue 1|WJG|www.wjgnet.com
to nociceptors becoming more sensitive to further 
stimulation. This peripheral sensitization may be caused 
by upregulation of  nerve growth factors, brain­derived 
neurotrophic factors and proinflammatory cytokines, 
and lead to increased pain intensity[60,61]. Pancreatic 
neuroplasticity (remodelling) and peripheral sensitization 
(increased excitability) will increase the nociceptive drive 
to the central nervous system resulting in an increased 
reaction of  pain transmitting neurons (increase of  
pain)[59]. Finally, this process may result in spontaneous 
nociceptive activity without the presence of  nociceptive 
inputs and to an aggressive increase of  pain signals to the 
spinal cord[16,62]. 
Is central pain processing altered?
QST-CP: Increasing evidence has been published on 
segmental and generalized hyperalgesia and referred pain 
as a sign of  spinal and supraspinal central sensitization 
in CP. Accordingly, decreased pain thresholds (i.e., 
hyperalgesia) for somatic stimulation in dermatomes near 
and distant to the pancreas in chronic pancreatitis patients 
are evident[7,11,13,27,54]. In agreement with this, other studies 
report increased areas of  referred pain to electrical 
stimulation of  viscera of  upper gastrointestinal organs 
and decreased pain thresholds to visceral stimulation 
of  the rectosigmoid[28,63]. These results suggest that 
peripheral visceral and somatic nerves converge at spinal 
levels in the central nervous system to elicit (somatic) 
referred pain as a sign of  spinal central sensitization[64,65]. 
Failure of  descending inhibitory pain modulation has 
also been observed in CP patients[11,25,27,28,54]. Probably 
this is due to a decreased activity in descending inhibitory 
pathways to the spinal cord as well as an increase in 
facilitatory activity projecting to the posterior spinal horn.
QST-visceral pain conditions: Similar to CP, sensitization 
of  the central nervous system is seen in other in­
flammatory visceral pain conditions e.g., esophagitis and 
inflammatory bowel disorders, where it can be local in 
the viscera, spreading in the surrounding area or more 
distant in the case of  referred pain. Drewes et al[66] showed 
segmental sensitization to thermal stimulation of  the distal 
esophagus in esophagitis patients, together with a larger 
referred somatic pain area to mechanical stimulation, both 
reflecting central sensitization. Comparable results were 
found in ulcerative colitis and Crohn’s disease patients, 
who showed decreased pain thresholds to balloon dilation 
of  the colon or rectal stimulationagain suggesting visceral 
hypersensitivity as a sign of  central sensitization[67­69]. 
Evidence for descending counter­regulatory mechanisms 
has been described for patients with peptic ulcer and 
Crohn’s disease, both of  whom showed hypoalgesia to 
visceral stimulation as a sign of  effective tonic descending 
inhibition[70­72]. 
Clinical application of  QST: In addition to characterization 
of  the pain mechanisms underlying visceral pain 
disorders, QST has been used to study the effects of  pain 
treatment on pain processing. In a study of  S­ketamine, 
a noncompetitive NMDA receptor antagonist whose 
activity is related to central sensitization, infusions in CP 
patients were associated with a short­lasting increase in 
pain pressure thresholds, without a reduction in clinical 
pain. However, this study was not powered on clinical 
endpoints and had a short infusion time[11]. Another study 
showed that pregabalin reduced clinical pain in CP and 
was associated with a moderate anti­hyperalgesic effect. 
Interestingly patients treated with placebo also showed 
a reduction in clinical pain, but this effect came without 
changes in pain thresholds measured by QST[12,15]. 
The role of  disease progression in CP and how it is 
influenced by interventions has not been well studied. 
Just one exploratory study in CP patients showed 
a relation between a more severe disease stage and 
lower pain thresholds (more hyperalgesia) compared 
to a moderate disease stage and healthy controls[27]. 
Interestingly, a study in CP patients after pain­relieving 
pancreatic surgery showed that patients with a poor pain 
outcome after surgery showed more central sensitization 
and more pronociceptive descending pain modulation 
compared to patients with a good pain outcome and 
healthy controls[73]. 
To summarize: CP and other abdominal visceral pain 
syndromes show similarities in pain mechanisms and 
physiology. In the area of  tissue damage and its surrounding 
tissue there is typically hypersensitivity to all kinds of  
different stimuli as signs of  segmental hyperalgesia. When 
pain is ongoing, tissues more distant of  the area of  injury 
also become sensitized as (generalized hyperalgesia) as a 
sign of  spreading central sensitisation. Failure of  counter­
regulatory mechanisms such as DNIC, measured via 
e.g., CPM, also leads to hyperalgesia and pain increases. 
Treatments aimed at central pain mechanisms may reduce 
pain and hyperalgesia in such patients. Evidence regarding 
the role of  disease progression and treatments aimed 
at reducing pain and central sensitization is still scarce. 
However, it is evident that QST can play a useful role in 
quantifying pain processing and its impact on clinical pain 
before and after pain treatment[74,75]. 
Resting state electroencephalography - CP: Olesen 
et al[76] reported an increase in amplitude strength in the 
theta and alpha band in patients with CP compared to 
healthy controls, reflecting slowed EEG rhythmicity in 
patients with CP compared to controls. Another study 
demonstrated a significant shift toward lower frequencies 
in patients with CP compared with healthy controls[33]. 
This was observed as a decrease in peak alpha frequency 
over all scalp electrodes. Interestingly, these changes 
correlated with duration of  pain, further supporting 
alterations in resting state EEG as a potential biomarker 
in chronic pain conditions.
The mechanisms underlying these observations 
are still poorly understood. One hypothesis is that of  
thalamocortical dysrythmia (TCD), where damage or 
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lesions to afferent neural pathways results in deafferentation 
and a decrease in excitatory input to the thalamic relay 
cells. This results in disfacilitation and cell membrane 
hyperpolarization due to activation of  T­type calcium 
channels. In this hyper­excitatory state thalamic relay 
neurons fire low threshold spike bursts and the normal 
thalamo­cortical rhythmicity is disturbed[30]. Application of  
drugs that interfere with T­type calcium channel function 
may prevent low frequency bursting, reverse TCD, and 
alleviate pain in conditions with underlying TCD. Thus 
resting state EEG may be of  value not only as a potential 
biomarker for chronic pain progression via shifts in 
oscillatory activity, but also in treatment decisions and 
evaluation via identification of  TCD. Another hypothesis 
is based on recent experiments indicating that the phase 
of  alpha activity modulates perception and that alpha 
oscillations are produced by periodic pulses of  inhibition. 
It was suggested that posterior alpha oscillations provide a 
mechanism for prioritizing and ordering unattended visual 
input according to “relevance” or saliency[32]. However, it is 
unclear whether the proposed role of  alpha activity can be 
generalized to other modalities, such as the somatosensory 
and nociceptive system.
Evoked brain potentials EEG - CP: Dimcevski et al[63] 
recorded EPs after stimuli given with a constant current 
electric stimulator at the three different sites of  the upper 
gastrointestinal tract. Patients with CP had a significantly 
decreased latency for the N1 and P1, while N2 latency 
was borderline significant compared to healthy subjects. 
No differences were found in the amplitudes of  the N1, 
P1, and N2 potentials. In another study using evoked 
visceral pain of  the upper gastrointestinal tract, patients 
showed higher activity than controls in the theta band, 
with prolonged persistence of  the signal and at lower 
frequency (4.4 Hz in patients compared to 5.5 Hz in 
controls)[10]. In a second study, patients with CP showed 
hyperalgesia to electrical stimulation and prolonged 
latencies of  early visceral EPs components in the frontal 
region of  the cortex compared to healthy controls. 
Additionally, scalp distributions of  EP amplitudes were 
more scattered and more posteriorly located in the 
patient group[28]. As the changes in cortical processing 
were correlated to the pain this further validates the 
findings. To date, no comparable data are available for 
other types of  abdominal focus­related chronic pain.
Clinical application of  EEG: Studies using EEG 
to identify patients who may benefit from treatment 
strategies targeting central pain mechanisms are limited. 
Graversen et al[77] studied the resting state EEG after a 
three week regimen of  pregabalin or matching placebo in 
patients with CP. Patients in the pregabalin group showed 
a significant increase in theta activity after pregabalin 
treatment, while no changes were observed for the other 
frequency bands, nor were any changes found in the 
placebo group. The authors concluded that quantitative 
pharmaco­EEG can be used to monitor central analgesic 
mechanisms of  pregabalin and may in the future be used 
to predict treatment effects[77]. 
To summarize: Studies in chronic visceral pain have 
investigated both the resting state as well as the evoked 
EEG. The use of  multiple analysis techniques and 
different stimulation methods makes these results difficult 
to compare. Alpha activity in the resting state EEG has 
been shown to be affected in multiple chronic pain states 
including CP, suggesting a change in the default state 
of  the brain as a result of  chronic pain. Pain­evoked 
EEG studies in CP patients demonstrate alterations in 
dynamic pain processing reflected by prolonged latencies 
of  visceral EPs and higher theta activity with prolonged 
persistence of  the signal at a lower frequency during 
experimental visceral pain. Taken together, these EEG 
findings further support the concept that chronic visceral 
pain conditions such as chronic pancreatitis are associated 
with significant and ubiquitous alterations in resting state 
and evoked CNS processing, both nociceptive and non­
nociceptive.
(f)MRI 
The cortical and subcortical structures that are involved in 
visceral pain are the thalamus from which signals further 
ascend to different parts of  the brain i.e., the limbic system 
(insula, cingulate cortex and prefrontal cortex), the primary 
(discriminating pain) and secondary (recognizing and 
remembering pain) somatosensory cortex[30]. In particular 
the insula has an important function in pain perception 
from the gut[78]. The functional relationship between 
these areas was described with DTI for healthy controls 
who underwent rectal distension[79]. Important areas for 
pain experience, influenced by cognitive, affective and 
emotional components, are processed in the limbic system. 
Other structures involved are: the amygdala, periaquaductal 
gray matter, reticular formation and hypothalamus. These 
structures are mostly related to pro­ and antinociceptive 
control such as descending pain control[80]. 
CP: A MRI study with DTI in CP patients showed 
increased diffusivity in grey matter regions of  the insula 
and cingulate cortex suggesting microstructural changes 
of  pain associated brain areas. These observations 
appeared to be directly correlated to the pain experienced 
by patients. Another MRI volumetry CP study supported 
these findings and showed cortical thinning in similar 
brain areas (the limbic system)[81]. Brain areas that are 
associated with descending pain modulation e.g., the 
cingulate cortex, hypothalamus and periaqueductal grey 
matter showed cortical thinning in some studies with CP 
patients. These results might explain impaired descending 
inhibition in chronic pancreatitis[28,81]. Overall, in CP 
patients different brain areas that are involved in visceral 
pain processing showed a decrease in cortical thickness. 
Whether these changes are due to chronic pain and how 
these changes influence pain processing is unknown at 
the moment.
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Visceral pain conditions: Studies in other abdominal 
visceral pain syndromes are scarce. However, similar 
results to studies in CP were found in patients with 
inflammatory bowel disease when they were compared to 
healthy controls[82]. 
Clinical application of  (f)MRI: At present there are 
no studies using (f)MRI to observe therapeutic effects or 
disease progression in CP. 
To summarize: Similarly to EEG studies, (f)MRI 
studies have shown for CP patients and other visceral 
pain syndromes that changes in brain activity are 
present particularly in areas that are related to pain 
processing such as the limbic system, hypothalamus and 
periaqueductal regions. However the role of  pain in these 
changes and how this influences pain perception is poorly 
understood at the moment.
Is altered central processing (still) dependent on 
peripheral nociceptive drive?
Central sensitization manifest as spreading hyperalgesia 
can ultimately become independent of  peripheral 
nociceptive input and no longer respond to treatments 
targeting the source of  nociception and/or achieving 
peripheral deafferentation i.e., nerve blocks and opioids. 
Changes in central pain processing independent of  
peripheral nociceptive input were supported by a study 
involving CP patients who had a splanchnic denervation 
to reduce pain, but where ca. 75% continued to 
experience painful and exhibit widespread hyperalgesia 
(4 years) after a technically successful procedure, 
suggesting real central autonomy[54,83]. Further literature 
on the reversibility of  central sensitisation is scarce. One 
study described two different groups of  patients with 
osteoarthritis after hip replacement surgery, one that 
showed reversibility of  hyperalgesia and a descending 
inhibitory modulation deficit and another group that had 
ongoing pain without changes in hyperalgesia and no 
changes in central inhibition suggesting the presence of  
central autonomy[18]. 
IMPLEMENTING A SYSTEMATIC 
MECHANISM-ORIENTATED APPROACH 
TO CHRONIC PAIN IN CLINICAL 
PRACTICE
Source of nociception
QST performed at the site of  the nociceptive focus can 
help identify the source of  nociception and provide 
insight into the nature and aggressiveness of  the 
nociceptive input involved (e.g., visceral pain). EEG and 
(f)MRI diagnostics have no role in this context.
Altered nociceptive transmission
QST performed close to the site of  nociception can 
be used to help diagnose peripheral sensitization (local, 
primary hyperalgesia, usually thermal) and nerve damage 
(classically thermal hypoalgesia and hypoaesthesia in the 
territory of  the nerve in question)[84­87]. Theoretically, 
evoked potential EEG studies could be used to quantify 
alterations in nociceptive transmission. However, most 
EP studies only involve large fibre non­nociceptive 
somatosensory processing; there are only a few such 
studies involving nociception­relevant small fibres (e.g., 
laser EPs).
Role of QST in describing altered central pain 
processing
QST measured close and distant to the site of  pain 
allows differentiation between segmental (spinal 
central sensitization) or generalized (supraspinal central 
sensitization) hyperalgesia. Stimulation of  different tissues 
(e.g., electrical skin stimulation, mechanical stimulation 
of  muscle by pressure algometry) can further help 
understand the source of  pain and spread of  associated 
altered pain processing. Dynamic QST measurements 
such as the CPM paradigm are helpful in diagnosing 
shifts in descending nociceptive modulation.
Is altered central processing (still) dependent on 
peripheral nociceptive drive?
In this case, central sensitization is present but no 
longer dependent on ongoing nociceptive input. Thus 
(trial) treatments aiming to deafferent the nociceptive 
source (e.g., nerve block or nerve transection) will not be 
accompanied by changes in central pain processing (e.g., 
spreading hyperalgesia) as measured by QST. As flanking 
­ mainly experimental ­ procedures, EEG and (f)MRI 
have made it possible to directly demonstrate cortical 
reorganization, altered connectivity and modulation in 
chronic pain conditions.
Clinical use
Diagnostics: At our institution, QST has proven useful 
to diagnose and monitor changes in pain processing 
accompanying chronic pain. Our research and clinical 
experience suggest that implementation of  a systematic 
mechanism­orientated approach to pain based on a simple 
diagnostic QST is both feasible and desirable in clinical 
pain practice. To this end we have instituted a simple 
QST screening paradigm, which all difficult chronic 
pain patients undergo [the Nijmegen­Aalborg screening 
QST (NASQ)][18]. The NASQ paradigm includes four 
measurement points measured bilaterally (close and 
distant to the site of  pain, thus providing topographical 
information), two stimulation modalities (electric and 
pressure stimulation) and a CPM paradigm (cold pressor 
task). Details are provided in Table 1[18]. 
The NASQ paradigm is well accepted by patients, 
easy to perform and learn, and can be completed within 
30 min. Thermal QST testing can be added to test 
specifically for peripheral nerve damage[18,88]. 
Regarding clinical use of  EEG and (f)MRI in 
chronic pain, the literature remains scarce. Furthermore 
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both investigations are onerous, time consuming and 
expensive. Therefore we do not at present recommend 
their use in daily clinical practice for chronic pain patients, 
reserving these techniques for research.
Therapeutics: The new approach to pain in CP presented 
here allows for holistic and systematic management of  CP 
pain. Such a systematic mechanism­orientated approach 
not only facilitates the diagnosis and prognosis of  chronic 
pain, it also provides the possibility of  monitoring signs of  
chronic pain progression. As such, it forms the basis for 
more rational choice of  treatment options to maximize 
treatment response, together with subsequent ongoing 
monitoring of  effectiveness of  chronic pain treatment.
Table 2 provides a summary of  our systematic 
mechanism­orientated approach to chronic pain, such as 
pancreatitis pain, as implemented at our institution. The 
scheme is based on the literature discussed in this review 
and our own clinical experience and practice.
CONCLUSION
Intense abdominal pain is the dominant feature of  CP. 
In this review we propose a new systematic mechanism­
orientated approach to the chronic pain of  CP. Multiple 
studies support that pain in CP is similar to other 
visceral pain syndromes such as inflammatory bowel 
disease. Increasing evidence has shown that changes 
in central pain processing are present and comparable 
in CP and other abdominal visceral pain syndromes. 
The data suggest that changes in pain processing due 
to chronic visceral pain are common and necessitate 
a targeted and mechanism­orientated diagnostic and 
therapeutic approach. This management approach needs 
to be holistic, including not only traditional treatments 
addressing the pancreas as a nociceptive source, but also 
specifically searching for ­ and therapeutically targeting ­ 
alterations in CNS processing of  pain.
As shown in this review, QST, EEG and (f)MRI can 
be useful diagnostic instruments to analyze central pain 
processing and help us in finding optimal mechanism­
orientated treatments for pain in CP and other chronic 
visceral pain syndromes. Future research should define 
the presence and pattern of  altered pain processing 
for specific chronic pain disorders and compare this 
with a healthy population using diagnostic tools such as 
QST, EEG and fMRI. Apart from characterization of  
hyperalgesia and descending pain modulation further 
questions need to be addressed. How does hyperalgesia 
develop over time? How is this influenced by disease 
progression and our treatments? What is the impact of  
gender and psychological state? Can we predict patients 
who are prone to chronic pain and altered central pain 
processing? The only way to increase our knowledge 
in this respect is to measure the effect of  pain and 
nociception on central pain processing in large­scale 
clinical studies using QST, EEG or fMRI before and 
after interventions and during disease progression[77]. This 
will help us evaluate therapies and guide us to the proper 
treatment for a specific patient at a specific disease stages. 
Such personalized medicine is the key to improved 
pain treatment and may pave the way to new and more 
Table 1  Nijmegen-Aalborg screening quantitative sensory testing paradigm[18]
NASQ paradigm
Standard QST
   Sites (bilateral) Trapezius muscle, thenar eminence, rectus femoris, abductor hallucis, site of pain
   Thresholds Pressure pain, electric detection, electric pain detection, electric pain tolerance
Conditioned pain modulation
   Sites 1 Ice-water bucket (non-dominant hand)
2 Thresholds on rectus femoris
   Thresholds (before ice-water/180 s after) Pressure pain, electric pain tolerance
Quantitative sensory testing (QST) measurements to detect central sensitization and pro- or anti-nociceptive shifts in descending pain modulation. NASQ: 
Nijmegen-Aalborg screening QST.
Table 2  Schematic for systematic mechanism-orientated approach to chronic pancreatitis pain
Questions Issue QST Therapy
Nociceptive source? Site/agressiveness Local hyperalgesia Treat or deafferent
Nociceptive transmission? Nerve damage Territorial thermal hyperalgesia Treat (cave CS!)
Central pain processing? Central sensitisation Spreading hyperalgesia Antihyperalgesia (ketamine, gabapentinoids)
Pronociceptive modulation Sensitisation to CPM paradigm Activate DI (TCA, NRI)
Autonomy of central pain 
processing?
Autonomy No changes in thresholds after 
therapy
Traget altered central processing
Autonomy means that alterations in central pain processing have become independent of peripheral nociceptive drive. CPM: Conditioned pain modulation; 
DI: Descending inhibition; TCA: Tricyclic antidepressant; NRI: Noradrenaline reuptake inhibitor; QST: Quantitative sensory testing. This figure is based on 
the original figure of ref [18].
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effective therapeutic approaches.
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